Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Indivior (INDV)

Price 789.50p on 14-02-2025 at 17:30:01
Change -2.50p -0.32%
Buy 787.00p
Sell 785.00p
Buy / Sell INDV Shares
Last Trade: Unknown 1,471.00 at 796.82255p
Day's Volume: 105,388
Last Close: 789.50p
Open: 806.00p
ISIN: GB00BN4HT335
Day's Range 785.00p - 808.50p
52wk Range: 555.00p - 1,770.00p
Market Capitalisation: £980m
VWAP: 793.67422p
Shares in Issue: 124m

Recent Trades History Indivior (INDV)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 1,471 796.82255p Currency Conversion
OTC Trade
16:38:40 - 14-Feb-25
Buy* 59,474 789.50p Suspected BUY Trade
16:35:13 - 14-Feb-25
Sell* 4 785.00p Automatic Execution
16:29:52 - 14-Feb-25
Sell* 130 786.00p Automatic Execution
16:27:36 - 14-Feb-25
Buy* 193 787.00p Automatic Execution
16:27:25 - 14-Feb-25
Sell* 280 786.00p Automatic Execution
16:26:07 - 14-Feb-25
Sell* 45 786.00p Automatic Execution
16:26:07 - 14-Feb-25
Sell* 33 787.00p Automatic Execution
16:19:38 - 14-Feb-25
Buy* 100 790.00p Automatic Execution
16:18:20 - 14-Feb-25
Sell* 61 789.50p Automatic Execution
16:17:19 - 14-Feb-25

Share Price History for Indivior

Time period:
to
Date Open High Low Close Volume

Share News for Indivior

UK earnings, trading statements calendar - next 7 days

13th Feb 2025 14:04

Read More

IN BRIEF: Indivior faces FDA delay on Sublocade label change

12th Feb 2025 09:18

Indivior PLC - Richmond, Virginia-based maker of medicines to treat substance use disorders - Says it is facing a delay in a review of label changes to Sublocade by the US Food & Drug Administration. The proposed label has been accepted but the final review has been delayed. Sublocade is a treatment for addiction to opioid drugs. Prior to the announcement, the company's share price was down 20% in February. Read More

IN BRIEF: Indivior completes USD100 million share buyback

4th Feb 2025 10:41

Indivior PLC - Richmond, Virginia-based maker of medicines to treat substance use disorders - Completes share buyback programme begun in July. Indivior buys back 9.4 million shares at average GBP8.25, worth GBP77.7 million, about USD100.0 million, in total. The buyback was run by Morgan Stanley & Co International PLC. Last week, Indivior promoted David Wheadon to chair, starting immediately. Wheadon joined the Indivior board in June last year. Wheadon is a medical doctor who worked for GlaxoSmithKline, now GSK PLC, and Eli Lilly & Co. Until 2019, he was senior vice president of global regulatory affairs, patient safety & quality assurance at AstraZeneca PLC. Read More

LONDON BROKER RATINGS: Indivior and Vistry price targets cut

3rd Jan 2025 09:28

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning: Read More

Indivior to talk with Oaktree after accusations of "value destruction"

8th Nov 2024 09:55

(Alliance News) - Indivior PLC on Friday said it would continue to engage with a leading shareholder which slammed the firm's "lack of focus" and "failure" to recognise a competitive threat. Read More

FTSE 100 Latest
Value8,732.46
Change-32.26

Login to your account

Forgot Password?

Not Registered